Global Antibacterial Market: Dearth of New Generation Drugs Warrants Emphasis on Product Development

Published Date : Feb 27, 2017

ALBANY, NY, Feb 27, 2017: has announced the addition of a new market study to its repository, titled “Global Antibacterial Drugs Market To 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance.”  The report throws light on the various facets of the market for antibacterial drugs, also known as antibiotics, which are administered to prevent or treat infectious diseases.

With the rising concern worldwide over antimicrobial resistance and its progression, the need for product development is of utmost importance in the market. The report brings to the fore the important developments in the market with a particular focus on drugs meant for treating tuberculosis, pneumonia, sepsis, and methicillin-resistant staphylococcus aureus (MRSA). The report predicts the global market for antibacterial drugs to attain a value of US$35.6 bn in 2022 from US$27.1 bn in 2015.

Drugs for thwarting bacterial infections are mostly vaccines, which enable the body’s immune system to fend off particular infections. However, numerous prophylactic monoclonal antibodies are also being developed at present. Drugs for treating bacterial infections are somewhat different from vaccines. Most popular are beta-lactam antibiotics, which include the well-known penicillin. Bacteria resistance, unfortunately, have grown to penicillin through the manufacture of beta-lactamase enzymes that damage the beta-lactam ring found inside the antibiotics, making them useless. Hence, modern beta-lactams are mostly a combination drugs of a beta-lactam and a beta-lactamase inhibitor.

For Sample Copy, click here:

Besides beta-lactams, other classes of drugs meant to cure bacterial infections are fluoroquinolones, which counter DNA gyrase and/or topoisomerase IV; and protein synthesis inhibitors, that help overcome bacteria resistant to beta-lactam antibiotics. However, bacteria have developed resistance against these drugs as well. The result: a gap in supply of new age drugs to up the ante against drug-resistant bacteria.

The report finds that vaccines currently hold a sway over the antibacterial market. The ones much sought after are those for preventing tetanus, pneumococcal infections, diphtheria, and pertussis. There have been recent additions such as therapies for antibiotic-resistant bacteria, including strains with multi-drug resistance. The number of such products is predicted to multiply in the next couple of years.

Further, the report attempts to gauge the size and potential of the antibiotic pipeline and how major companies are attempting to overcome the antibiotic resistance. It throws light on the degree of impact approval of new products and the patent expiries of existing ones will have on the global antibacterial drugs market’s trajectory in the near future.

The report also discusses popular molecular targets in the pipeline and the possibilities of commercial success for late-stage pipeline products. It forecasts the market size and discusses key participants in the market. Some such companies are Allergan, Pfizer, Merck & Co, Roche, GlaxoSmithKline, and Bayer. 

To order report Call Toll Free: 866-997-4948 or send an email on